Build the best technology platform with translatable NHP models and access to large population of patients to enable translational research from NHP to human using imaging and other biomarkers.
In 2018 PriMed Initiated Collaboration in Ophthalmology with Harvard Mass. Eye and Ear.
In 2018 Harvard Mass. Eye and Ear. and PriMed Bio-tech Group Co., Ltd, a leading science-driven, technologically advanced, high-quality preclinical research partner, initiated collaboration in ophthalmology in PriMed NHP colony.
The Successful 3-year On-site Review of AAALAC Certification
On March 5, 2018, PriMed Bio-tech Group Co., Ltd, a leading science-driven, technologically advanced, high-quality preclinical research partner, received the 3-year on-site review from the Association for the Assessment and Accreditation
Primed is a Cutting Edge Translational Research Company devoted to understanding and overcoming human diseases.
Primed has extensive expertise and significant experience in non-human primate research, as well as identifying and developing specialized animal models of human disease, helping global biomedical research community solve challenges in Metabolic disease, Eye disease, Cardiovascular diseases, NAFLD/NASH, Autoimmune diseases and Kidney disease.
Primed's research facilities are AAALAC accredited and GLP compliant, providing expertise from disease model validation to IND-enabling study design and execution for over 100 global partners.
Primed has well-established multi-modality imaging capabilities and extensive expertise in developing and applying imaging biomarkers for drug discovery and development with 11 different imaging modalities available for studies.
